AMRX

Amneal Pharmaceuticals Inc

20.48

Oct 22 • 3:59 PM ET +0.28 (1.39%)

20.03

Aftermarket • 7:30 PM ET -0.45 (-2.20%)

Healthcare Drug Manufacturers - Specialty & Generic USA Mid NASD

Peers: TEVA VTRS RDY ANIP AMPH ALVO SUPN PRGO BHC OGN

| Held by: IJR VTI VB IWM VBR DFAS XSMO VXF SPSM IWN

Scroll to Statements

Index	RUT
Market Cap	6.54B
Enterprise Value	9.28B
Income	157.36M
Sales	3.12B
Book/sh	0.10
Cash/sh	0.43
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	8500
IPO	Dec 19, 1995

P/E	42.74
Forward P/E	17.02
PEG	0.83
P/S	2.10
P/B	198.03
P/C	47.99
P/FCF	80.63
EV/EBITDA	13.82
EV/Sales	2.98
Quick Ratio	1.44
Current Ratio	2.20
Debt/Eq	84.55
LT Debt/Eq	80.87
Option/Short	Yes / Yes

EPS (ttm)	0.48
EPS next Y	1.20
EPS next Q	0.24
EPS this Y	23.76%
EPS next Y	17.17%
EPS next 5Y	20.48%
EPS past 3/5Y	- -18.36%
Sales past 3/5Y	10.92% 8.66%
EPS Y/Y TTM	4917.17%
Sales Y/Y TTM	9.28%
EPS Q/Q	152.81%
Sales Q/Q	9.89%
Earnings	Nov 03 BMO
EPS/Sales Surpr.	34.83% 3.64%

Insider Own	55.02%
Insider Trans	-0.25%
Inst Own	48.23%
Inst Trans	1.02%
ROA	4.37%
ROE	-
ROIC	5.82%
Gross Margin	39.32%
Oper. Margin	15.30%
Profit Margin	5.05%
SMA20	3.01%
SMA50	9.25%
SMA200	32.12%
Trades

Shs Outstand	319.33M
Shs Float	143.63M
Short Float	7.85%
Short Ratio	4.40
Short Interest	11.28M
52W High	21.17 -3.28%
52W Low	9.99 105.01%
Volatility	2.56% 3.37%
ATR (14)	0.68
RSI (14)	62.26
Beta	1.26
Rel Volume	2.36
Avg Volume	2.56M
Volume	6,036,769

Perf Week	6.39%
Perf Month	5.95%
Perf Quarter	14.29%
Perf Half Y	61.90%
Perf YTD	62.54%
Perf Year	96.36%
Perf 3Y	490.20%
Perf 5Y	261.20%
Perf 10Y	-6.27%
Recom	1.12
Target Price	23.00
Prev Close	20.20
Price	20.48
Change %	1.39%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-23-26	Initiated	Oppenheimer	Outperform	$27
Sep-09-26	Initiated	Leerink Partners	Outperform	$23
Apr-17-26	Initiated	UBS	Buy	$19
Dec-09-25	Initiated	Barclays	Overweight	$15
Jun-06-25	Initiated	Goldman	Buy	$12
Feb-24-25	Upgrade	JP Morgan	Neutral → Overweight	$9 → $12
Sep-06-24	Upgrade	JP Morgan	Underweight → Neutral	$9
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform	$5
Mar-08-21	Upgrade	Goldman	Sell → Buy	$4 → $6.50
Dec-14-20	Upgrade	Guggenheim	Neutral → Buy	$5.50
Dec-14-20	Upgrade	Barclays	Equal Weight → Overweight	$4.50 → $6
Jul-27-20	Initiated	Goldman	Sell	$4
May-12-20	Upgrade	Guggenheim	Sell → Neutral
Dec-12-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-12-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform	$11 → $5
Jul-11-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$11 → $6
Jul-08-19	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-11-19	Initiated	Barclays	Equal Weight	$9

Show Previous Ratings

Oct-08-26 08:00AM	Amneal to Report Third Quarter 2026 Results on November 3, 2026 (GlobeNewswire)
Sep-21-26 06:17AM	Ipsen Shares Fall After Early Launch of U.S. Generic Rival (The Wall Street Journal) +7.75%
Sep-18-26 04:01PM	Amneal Announces FDA Approval and Launch of Lanreotide Injection (GlobeNewswire)
Aug-10-26 08:00AM	Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader (GlobeNewswire)
Jul-30-26 10:50PM	Amneal Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary (Moby)
05:02PM	Loading…
05:02PM	Amneal Pharmaceuticals Inc (AMRX) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ... (GuruFocus.com)
06:00AM	Amneal Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-17-26 08:00AM	Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations (GlobeNewswire)
Jul-09-26 04:05PM	Amneal to Report Second Quarter 2026 Results on July 30, 2026 (GlobeNewswire)
Jun-29-26 03:00AM	Zambon and Amneal Announce Positive CHMP Opinion for Hopledo (IPX203) for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations (GlobeNewswire)
Jun-10-26 10:09AM	Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals (PR Newswire)
Jun-05-26 08:00AM	Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT in Parkinson's Disease (GlobeNewswire)
Jun-04-26 08:00AM	Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution (GlobeNewswire) +5.01%
Jun-01-26 08:00AM	Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026 (GlobeNewswire)
May-07-26 04:01PM	Amneal Reports First Quarter 2026 Financial Results (GlobeNewswire)
08:30AM	Loading…
Apr-22-26 08:30AM	Amneal Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary (Moby)
06:17AM	Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader (Business Wire)
06:00AM	Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance (GlobeNewswire)
Apr-20-26 08:00AM	Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT for Parkinson's Disease, Including Over 3 More Hours of Daily "Good On" Time When Switching from RYTARY (GlobeNewswire)
Apr-14-26 08:00AM	Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S. (GlobeNewswire)
Apr-10-26 08:11PM	Is AMRX Stock Undervalued? Sales Multiple, Target, Upside (Quartz)
08:11PM	Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing (Quartz)
08:11PM	AMRX: 3 Growth Drivers Behind Amneal's 2026 Outlook (Quartz)
Apr-09-26 08:00AM	Amneal Launches Bimatoprost Ophthalmic Solution, 0.01% (GlobeNewswire)
Apr-07-26 04:01PM	Amneal to Report First Quarter 2026 Results on May 1, 2026 (GlobeNewswire)
08:00AM	Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson's Awareness Month (GlobeNewswire)
Mar-10-26 12:02AM	3 Reasons to Avoid AMRX and 1 Stock to Buy Instead (StockStory)
Mar-09-26 08:22AM	New Strong Buy Stocks for March 9th (Zacks)
07:11AM	Best Value Stocks to Buy for March 9th (Zacks)
Mar-05-26 04:05PM	Amneal to Participate in Upcoming Investor Conference (GlobeNewswire)
04:04PM	Loading…
Feb-27-26 04:04PM	Amneal Pharmaceuticals Inc (AMRX) Q4 2025 Earnings Call Highlights: Strong Financial Growth and ... (GuruFocus.com)
03:21PM	Why Amneal (AMRX) Stock Is Trading Lower Today (StockStory)
10:24AM	Amneal Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
09:30AM	Amneal (AMRX) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
09:17AM	Generic Drugs Focused Amneal Pharmaceuticals Revenue Crosses $800 Million (Benzinga)
07:15AM	Amneal Pharmaceuticals (AMRX) Q4 Earnings Top Estimates (Zacks)
06:39AM	Amneal (NASDAQ:AMRX) Beats Q4 CY2025 Sales Expectations (StockStory)
06:00AM	Amneal Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-25-26 10:03PM	Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow (StockStory)
Feb-23-26 09:40AM	Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now? (Zacks)
09:06AM	Viatris Stock to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-19-26 09:53AM	Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-18-26 04:05AM	Amneal Pharmaceuticals, Inc. (AMRX) Added to S&P SmallCap 600 Index, Boosting Investor Visibility (Insider Monkey)
Feb-13-26 11:26AM	Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market (PR Newswire)
Feb-12-26 11:31PM	3 Russell 2000 Stocks We Find Risky (StockStory)
Feb-09-26 09:40AM	Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-06-26 01:58PM	Mettler-Toledo Q4 Earnings Top Estimates, Sales Rise Y/Y (Zacks)
Feb-05-26 09:40AM	Is Amneal Pharmaceuticals (AMRX) a Great Value Stock Right Now? (Zacks)
Feb-04-26 11:32PM	3 Small-Cap Stocks That Fall Short (StockStory)
Feb-03-26 11:23AM	IQVIA Set to Report Q4 Earnings: Here's What You Should Know (Zacks)
Jan-28-26 04:05PM	Amneal Pharmaceuticals Added to S&P SmallCap 600 Index (GlobeNewswire)
12:10PM	Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:11AM	Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings? (Zacks)
Jan-27-26 06:02PM	TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600 (PR Newswire)
12:59PM	HCA Healthcare Q4 Earnings Beat Estimates on Strong Patient Volumes (Zacks)
08:00AM	Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026 (GlobeNewswire)
Jan-25-26 11:02PM	2 Reasons to Sell AMRX and 1 Stock to Buy Instead (StockStory)
Jan-22-26 09:40AM	Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? (Zacks)
Jan-15-26 09:40AM	Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock? (Zacks)
Jan-13-26 09:04PM	Amneal Pharmaceuticals Eyes 2026 Growth at JPMorgan, Crexont Sales Seen Doubling in 2025 (MarketBeat)
Jan-10-26 02:57PM	Truist Raises PT on Amneal Pharmaceuticals (AMRX) to $15 From $14 (Insider Monkey)
Jan-07-26 02:55PM	Can This Healthcare Stock Keep Going After a Nearly 70% Surge? (Barchart)
Jan-06-26 11:44AM	ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now? (Zacks)
Dec-22-25 04:01PM	Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia and XGEVA (GlobeNewswire)
04:00PM	mAbxience and Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia and XGEVA (PR Newswire)
Dec-09-25 04:01PM	Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals (GlobeNewswire)
Dec-05-25 08:00AM	Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT for Parkinson's Disease (GlobeNewswire)
Dec-02-25 08:00AM	Amneal to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:00AM	Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol (GlobeNewswire)
Dec-01-25 04:01PM	Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05% (GlobeNewswire)
Nov-28-25 10:56AM	ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick? (Zacks)
Nov-21-25 08:04AM	Why 2025 is a Dynamic and Transformative Year for Collegium (Zacks)
Nov-19-25 10:33PM	Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks (StockStory)
Nov-14-25 08:44AM	ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell? (Zacks)
05:10AM	Piper Sandler Lifts Amneal Pharmaceuticals, Inc. (AMRX)'s Price Target To $13 Following Q3 Earnings Beat (Insider Monkey)
Nov-13-25 04:01PM	Amneal Receives U.S. FDA Approval for Iohexol Injection (GlobeNewswire)
Nov-11-25 11:35PM	3 Stocks Under $50 We Steer Clear Of (StockStory)
Nov-04-25 09:33AM	Implied Volatility Surging for Amneal Pharmaceuticals Stock Options (Zacks)
Oct-31-25 01:00PM	Why Amneal (AMRX) Stock Is Up Today (StockStory) +8.20%
Oct-30-25 04:30PM	Amneal Pharmaceuticals Inc (AMRX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
09:30AM	Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
07:15AM	Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates (Zacks)
06:47AM	Amneal (NASDAQ:AMRX) Beats Q3 Sales Expectations, Stock Soars (StockStory)
06:14AM	Amneal: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Amneal Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-29-25 04:05PM	Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol (GlobeNewswire)
09:39AM	What To Expect From Amneal Pharmaceuticals Inc (AMRX) Q3 2025 Earnings (GuruFocus.com)
Oct-28-25 11:17PM	Amneal Earnings: What To Look For From AMRX (StockStory)
05:10PM	Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-27-25 10:00AM	BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy? (Zacks)
08:00AM	Amneal Launches Brekiya - the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches (GlobeNewswire)
Oct-23-25 10:00AM	Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-21-25 10:42PM	Amneal Pharmaceuticals, Inc. (AMRX): A Bull Case Theory (Insider Monkey)
Oct-07-25 09:40AM	Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now? (Zacks)
Oct-06-25 08:07AM	Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus (Zacks)
08:00AM	Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR (omalizumab) (Business Wire)
Oct-03-25 09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? (Zacks)
Oct-02-25 09:40AM	Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? (Zacks)
08:18AM	3 Lesser-Known Healthcare Names With Major Upside in Store (MarketBeat)
Oct-01-25 01:44PM	Amneal Pharmaceuticals, Inc. (AMRX) Files BLA for XOLAIR Biosimilar, Targets Multi-Billion-Dollar Market (Insider Monkey)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BUCHI J KEVIN	Director	Sep 11 '26	Option Exercise	14.45	20,445	295,430	95,522	Sep 14 04:10 PM
Kiely John	Director	Aug 13 '26	Sale	17.64	50,000	882,000	210,252	Aug 14 04:29 PM
Shah Nikita	Executive Vice President	Aug 12 '26	Sale	17.51	146,403	2,563,517	253,390	Aug 13 04:22 PM
Daly Jason B.	EVP, Chief Legal Officer	Aug 12 '26	Sale	17.40	210,000	3,654,000	35,171	Aug 13 04:21 PM
Daly Jason B.	EVP, Chief Legal Officer	Aug 11 '26	Sale	17.70	6,613	117,050	245,171	Aug 13 04:21 PM
JOHN KIELY	Director	Aug 13 '26	Proposed Sale	17.59	50,000	879,714		Aug 13 04:15 PM
NIKITA SHAH	Officer	Aug 12 '26	Proposed Sale	17.47	146,403	2,556,975		Aug 12 04:18 PM
JASON DALY	OFFICER	Aug 11 '26	Proposed Sale	17.36	210,000	3,646,285		Aug 12 04:11 PM
BUCHI J KEVIN	Director	Aug 11 '26	Proposed Sale	17.31	168,573	2,917,998		Aug 11 12:32 PM
Autor Deborah M.	Director	May 11 '26	Sale	12.94	34,819	450,558	93,660	May 12 04:10 PM
DEBORAH AUTOR	DIRECTOR	May 11 '26	Proposed Sale	12.94	34,819	450,416		May 11 06:56 PM
Nark Ted C	Director	Nov 17 '25	Sale	11.72	50,000	586,000	291,029	Nov 19 04:21 PM
Nark Ted C	Director	Nov 17 '25	Proposed Sale	11.82	50,000	591,250		Nov 17 03:06 PM
Shah Nikita	Executive Vice President	Nov 12 '25	Option Exercise	2.75	131,856	362,604	278,259	Nov 14 05:13 PM
Shah Nikita	Executive Vice President	Nov 12 '25	Sale	11.92	131,856	1,571,724	146,403	Nov 14 05:13 PM
NIKITA SHAH	OFFICER	Nov 12 '25	Proposed Sale	11.92	131,856	1,571,723		Nov 12 05:12 PM

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

Co-FounderMr. Chirag K. Patel

Co-FounderMr. Chintu Patel R.Ph.

Executive VP & CFOMr. Anastasios G. Konidaris

Executive VPMr. Jason B. Daly Esq.

Executive VP & Chief Human Resources OfficerMs. Nikita Shah

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AMRX

Amneal Pharmaceuticals Inc

Upgrade your Finviz experience